A Clinical Trial Comparing Ramucirumab to Best Supportive Care in Patients with Liver Cancer Following Treatment with Sorafenib

What we are studying

If you fulfill all criteria for participation and agree to be in this research study, you will be “randomized” into one of the study groups described below. Randomization means that you are placed into a group by chance (like the flip of a coin). Neither you nor the study doctor will know what medicine you are taking. Whether you receive ramucirumab or placebo will be determined by chance. For this study, a placebo is a liquid that looks like the study drug but has no medicine. The chance that you will get ramucirumab is 2 in 3. All patients will receive best supportive care in addition to ramucirumab or placebo. You will be given the study drug by injection into your vein by the study staff. Treatment will continue with either ramucirumab 8 mg/kg or placebo, each with best supportive care, until you or your study doctor decide you should no longer continue in the study. The duration of your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive. One cycle is 2 weeks. You will receive treatment until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. Following completion of your treatment, you may be asked to return for follow-up visits or your study doctor or site staff will contact you from time to time to see how you are doing.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosis of hepatocellular carcinoma
  • Prior treatment with sorafenib
  • Documentation of disease progression during or after sorafenib
  • AFP>=400Ng/Ml
  • Adequate organ function

What is involved

  • Physical exam at each cycle
  • Heart function studies (ECG
  • Blood work at each cycle
  • Urinalysis at each cycle
  • Questionnaires at each cycle
  • Tumor assessments every 6 weeks for 6 months; then every 9 weeks


Patients will receive travel reimbursement and reimbursement for parking

Contact Information

Study Coordinator
Amy Neal, RN
Principal Investigator
Angela Alistar, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.